Gene products differentially expressed in cancerous cells

• US 7,700,359 B2
• Filed: 09/22/2004
• Issued: 04/20/2010
• Est. Priority Date: 06/02/2000
• Status: Expired due to Fees

• Current Assignee: Novartis Vaccines And Diagnostics Incorporated (Novartis Ag)
• Original Assignee: Novartis Vaccines And Diagnostics Incorporated (Novartis Ag)
• Inventors: Hansen, Rhonda, Randazzo, Filippo, Moler, Edward J., Lamson, George, Garcia, Pablo Dominguez, Escobedo, Jaime, Sudduth-Klinger, Julie, Kaufmann, Joerg, Reinhard, Christoph, Chan, Vivien W., Kennedy, Giulia C.
• Primary Examiner(s): Martinell; James
• Application Number:
  US10/948,737
• Publication Number:
  US 20070010469A1
• Time in Patent Office: 2,036 Days
• Field of Search: None
• US Class Current: 436/6
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: C12Q 1/6886 for cancer immunoassay for cancer G01N33/574
• CPC Class Codes: C12Q 2600/112 Disease subtyping, staging or classification
• CPC Class Codes: C12Q 2600/136 Screening for pharmacological compounds

Abstract

The present invention provides polynucleotides, as well as polypeptides encoded thereby, that are differentially expressed in cancer cells. These polynucleotides are useful in a variety of diagnostic and therapeutic methods. The present invention further provides methods of reducing growth of cancer cells. These methods are useful for treating cancer.

Claims

1. A method for assessing the colorectal tumor burden of a subject, said method comprising:

comparing a level of a DKFZ gene product in a patient sample to a control, wherein an increase in the level of the DKFZ gene product in the patient sample relative to the control is indicative of an increased colorectal tumor burden in the subject,

wherein the DKFZ gene product is a nucleic acid comprising a nucleotide sequence of SEQ ID NO;

3018, or a full complement thereof, or a polypeptide comprising an amino acid sequence of SEQ ID NO;

3017.

2. The method of claim 1, wherein the increase in the level of the DKFZ gene product in the patient sample relative to the control that is indicative of an increased tumor burden in the subject is at least a 1.5 fold increase.

3. A method for detecting a cancerous cell, said method comprising:

comparing a level of DKFZ gene product in a patient sample to a control,

wherein an increase in the level of DKFZ gene product in the patient sample relative to the control is indicative of the presence of a cancerous cell,

wherein the DKFZ gene product is a nucleic acid comprising a nucleotide sequence of SEQ ID NO;

3018, or a full complement thereof, or a polypeptide comprising an amino acid sequence of SEQ ID NO;

3017, and

wherein the cancerous cell is a colorectal cancer cell.

4. The method of claim 3, wherein the increase in the level of DKFZ gene product in the patient sample relative to the control that is indicative of the presence of a cancerous cell is at least a 1.5 fold increase.

5. A method of diagnosing colorectal cancer in a patient, said method comprising:

comparing a level of DKFZ gene product in a patient sample to a control level, said DKFZ gene product comprising a nucleotide sequence of SEQ ID NO;

3018, or a full complement thereof, wherein an increase in the level of DKFZ gene product in the patient sample relative to the control level is indicative of the presence of colorectal cancer in the patient.

6. The method of claim 5 wherein the increase in the level of DKFZ gene product in the patient sample relative to the control level that is indicative of the presence of colorectal cancer in the patient is at least a 1.5 fold increase.

7. A method of diagnosing colorectal cancer in a patient, said method comprising:

(a) contacting a polynucleotide that binds to mRNA encoding a DKFZ polypeptide comprising an amino acid sequence of SEQ ID NO;

3017 with nucleic acids of a biological sample acquired from said patient under binding conditions suitable to form a duplex; and

(b) comparing the amount of the duplex formed to the amount of duplex formed when the polynucleotide is contacted with nucleic acids of a biological sample acquired from a normal control, wherein an increase in the amount of duplex formed upon contacting said polynucleotide and said nucleic acids of the biological sample acquired from said patient compared to the amount of duplex formed upon contacting said polynucleotide and said nucleic acids of the biological sample acquired from a normal control is indicative of the presence of cancer in said patient.

8. The method of claim 7 wherein the presence of cancer is indicated by at least a two-fold increase in the amount of duplex formed from the patient sample as compared to the amount of duplex formed from the normal control.

9. The method of claim 7, wherein the increase in the amount of duplex formed upon contacting said polynucleotide and said nucleic acids of the biological sample acquired from said patient compared to the amount of duplex formed upon contacting said polynucleotide and said nucleic acids of the biological sample acquired from a normal control that is indicative of the presence of cancer in said patient is at least a 1.5 fold increase.